Biochemical Bone Markers in Prostate Cancer Patients with Advanced Bone Metastasis
journal of kerbala university,
2014, Volume 10, Issue 2, Pages 143-149
AbstractProstate cancer is now recognized as one of the most important medical problems facing the male population and it is one of the most common cancer types. For this reason led us to investigate the prostate tumor markers for detection prostate cancer. In advanced stages, the prostate cancer is metastasis and arrived to the bone this led to lose of bone mineral density (BMD) and cause osteoporosis, therefor we measured urinary deoxypyridinoline (DPD) as a marker of collagen degradation activity, serum total-alkaline phosphatase activity, and measurement of calcium and phosphate as minerals of bone. This study included 46 patients with prostate tumor their ages ranging (50-80) year and 30 healthy subjects, matched in age with patients as control. Patients were classified according to stage of tumor. 7 patients with benign prostate hyperplasia (B.P.H) , 39 patients with carcinoma, 24 patients with metastasis prostate cancer (M.P.C), and 15 patients with localized prostate cancer (L.P.C). The results showed a significant (p< 0.0001) increase in levels of PSA, DPD, T-ALP, Ca+2 and PO4-3 in prostate tumor compared with the control group. In addition the results revealed a high significant (p < 0.000) increase in the level of urine DPD , serum PSA in patients with M.P.C compared with L.P.C and B.P.H patients, also there was a high significant (p < 0.01) increase in the level of Ca+2 and PO4-3 in patients with MPC compared with L.P.C and BPC patients. The data suggest that serial monitoring of deoxypyridinoline (DPD) could be clinically useful as marker of metastatic bone tumors and for treatment monitoring.
- Article View: 20
- PDF Download: 12